---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-113364"
form_type: "8-K"
ticker: "SLN"
cik: "0001479615"
company_name: "Silence Therapeutics plc"
filed_at: "2025-05-06T23:59:59+00:00"
generated_at: "2026-05-22T11:30:27.676229+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Silence Therapeutics appoints Tim McInerney to board; James Ede-Golightly to retire at June 2025 AGM

## Summary
- Tim McInerney appointed director effective May 5, 2025; will chair Remuneration Committee and join Audit and Risk Committee.
- James Ede-Golightly to retire at end of his term at 2025 AGM (June 26); steps down as Remuneration Committee chair immediately.
- McInerney receives $56,000 annual retainer, initial option for 48,000 ordinary shares (36-month monthly vest), and annual grant of same.
- McInerney brings 30+ years pharma/healthcare investment banking and executive experience; served on boards of Emisphere, Insite Vision, etc.

## SEC filing metadata
- accession: 0001193125-25-113364
- form_type: 8-K
- ticker: SLN
- cik: 0001479615
- company_name: Silence Therapeutics plc
- filed_at: 2025-05-06T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1479615/000119312525113364/0001193125-25-113364-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1479615/000119312525113364/d70963d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-113364
- JSON: https://secwatch.observer/filing/0001193125-25-113364.json
- Plain text: https://secwatch.observer/filing/0001193125-25-113364.txt

## Key facts
- Executive change
  Tim McInerney was appointed as Director at Silence Therapeutics plc.
  - Action: appointed
  - Role: Director
  source text: On May 5, 2025, upon the recommendation of the Nominations Committee, the Board appointed Tim McInerney to serve as a director of the Company, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1479615/000119312525113364/0001193125-25-113364-index.htm
- Executive change
  James Ede-Golightly departed as Director at Silence Therapeutics plc.
  - Action: retire
  - Role: Director
  source text: On May 5, 2025, James Ede-Golightly notified the board of directors (the “ Board ”) of Silence Therapeutics plc (the “ Company ”) of his decision to retire from the Board following the end of his current term, which expires at the end of the Company’s 2025 Annual General Meeting of Shareholders, which is anticipated to be held on June 26, 2025 (the “ 2025 AGM ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1479615/000119312525113364/0001193125-25-113364-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.